AbCellera Biologics Inc. Deferred Income Tax Expense (Benefit)
AbCellera Biologics Inc. (ABCL) reported Deferred Income Tax Expense (Benefit) of $1.96 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2024-02-20
- AbCellera Biologics Inc. deferred income tax expense (benefit) for the quarter ending 2021-12-31 was $1.25M.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for the quarter ending 2021-09-30 was -$4.02M.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for the quarter ending 2021-06-30 was $133.00K.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for the quarter ending 2021-03-31 was $623.00K.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for fiscal 2023 was $1.96M.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for fiscal 2022 was -$2.11M.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for fiscal 2021 was -$2.02M, a 196.19% decline from fiscal 2020.
- AbCellera Biologics Inc. deferred income tax expense (benefit) for fiscal 2020 was $2.10M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.96M 10-K · filed 2024-02-20 | |||
| 2022-12-31 | -$2.11M 10-K · filed 2024-02-20 | |||
| 2021-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$2.77M derived: sum of 2 quarters · filed 2024-02-20 | -$2.64M derived: sum of 3 quarters · filed 2024-02-20 | -$2.02M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$3.89M derived: sum of 2 quarters · filed 2021-11-10 | -$3.27M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $756.00K 10-Q · filed 2021-08-13 | ||
| 2021-03-31 | $623.00K 10-Q · filed 2021-05-14 | |||
| 2020-12-31 | $2.10M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |